The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
Open accessAbstract
BACKGROUND: Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data. METHODS: In a multicenter, single-blind, noninferiority trial, we randomly assigned 1208 patients with neovascular AMD to receive intravitreal injections of ranibizumab or bevacizumab on either a monthly schedule or as needed with monthly evaluation. The primary outcome was the mean change in visual acuity at 1 year, with a noninferiority limit of 5 letters on the eye chart. RESULTS: Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively. Bevacizumab administered as needed was equivalent to ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively. Ranibizumab as needed was equivalent to monthly ranibizumab, although the comparison between bevacizumab as needed and monthly bevacizumab was inconclusive. The mean decrease in central retinal thickness was greater in the ranibizumab-monthly group (196 μm) than in the other groups (152 to 168 μm, P=0.03 by analysis of variance). Rates of death, myocardial infarction, and stroke were similar for patients receiving either bevacizumab or ranibizumab (P>0.20). The proportion of patients with serious systemic adverse events (primarily hospitalizations) was higher with bevacizumab than with ranibizumab (24.1% vs. 19.0%; risk ratio, 1.29; 95% confidence interval, 1.01 to 1.66), with excess events broadly distributed in disease categories not identified in previous studies as areas of concern. CONCLUSIONS: At 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule. Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly. Differences in rates of serious adverse events require further study. (Funded by the National Eye Institute; ClinicalTrials.gov number, NCT00593450.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of CATT participants (>92%) had stable or improved VA relative to baseline.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The Comparison of AMD Treatments Trials (CATT) showed that bevacizumab was equivalent to ranibizumab in improving visual acuity (VA) of patients with neovascular AMD when treatment was administered either monthly or pro re nata (PRN).1”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“However, despite this remarkable clinical effect, there was a wide range in treatment response.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“At one year, participants treated monthly with bevacizumab or ranibizumab gained 8.0 and 8.5 letters, respectively, and those treated as needed gained 5.9 and 6.8 letters, respectively.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,781
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 4,204
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
New Visual Acuity Charts for Clinical Research
Ferris, F. L., Kassoff, A., Bresnick, G. H., & Bailey, I. L. (1982) · American Journal of Ophthalmology · doi:10.1016/0002-9394(82)90197-0 · Cited by 2,147
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M., CASTELLARIN, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,134
Fung, A. E., Lalwani, G. A., Rosenfeld, P. J., Dubovy, S. R., Michels, S., Feuer, W. J., Puliafito, C. A., Davis, J. L., Flynn, H. W., & Esquiabro, M. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.01.028 · Cited by 972
Cited by
Sorted by citations
Items 301–400 of 1,009
Stein, J. D., Newman-Casey, P. A., Tavag, M., Lee, P. P., & Hutton, D. W. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.037 · Cited by 85
Meredith, T. A., McCannel, C. A., Barr, C. C., Doft, B. H., Peskin, E., Maguire, M. G., Martin, D. F., & Prenner, J. L. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.10.027 · Cited by 84
Sheffield, V. C., & Stone, E. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1012354 · Cited by 84
Woo, S. J., Veith, M., Hamouz, J., Ernest, J., Zalewski, D., Studnička, J., Vajas, A., Papp, A., Vogt, G., Luu, J. K., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.5053 · Cited by 86
Dakin, H., Wordsworth, S., Rogers, C. A., Abangma, G., Raftery, J. P., Harding, S. P., Lotery, A. J., Downes, S. M., Chakravarthy, U., Reeves, B. C., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005094 · Cited by 85
Abedi, F., Wickremasinghe, S., Richardson, A. J., Makalic, E., Schmidt, D. F., Sandhu, S. S., Baird, P. N., & Guymer, R. H. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.006 · Cited by 84
Ashraf, M., Souka, A., & Adelman, R. A. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13565 · Cited by 86
Choriocapillaris Degeneration in Geographic Atrophy
Sohn, E. H., Flamme‐Wiese, M. J., Whitmore, S. S., Workalemahu, G., Marneros, A. G., Boese, E. A., Kwon, Y. H., Wang, K., Abràmoff, M. D., Tucker, B. A., et al. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.04.005 · Cited by 83
Shahzad, H., Mahmood, S., McGee, S., Hubbard, J., Haque, S. M., Paudyal, V., Denniston, A. K., Hill, L. J., & Jalal, Z. (2023) · Systematic Reviews · doi:10.1186/s13643-023-02261-x · Cited by 88
Wolf, A., & Kampik, A. (2014) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-013-2562-6 · Cited by 86
Pham, B., Thomas, S. M., Lillie, E., Lee, T., Hamid, J. S., Richter, T. A., Janoudi, G., Agarwal, A., Sharpe, J. P., Scott, A., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022031 · Cited by 84
Moorthy, R. S., Moorthy, M. S., & Cunningham, E. T. (2018) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000530 · Cited by 82
SUSTAINED ELEVATION OF INTRAOCULAR PRESSURE AFTER INTRAVITREAL ANTI-VEGF AGENTS
Dedania, V. S., & Bakri, S. J. (2015) · Retina · doi:10.1097/iae.0000000000000520 · Cited by 82
Sponer, U., Waldstein, S. M., Kundi, M., Ritter, M., Golbaz, I., Heiling, U., Papp, A., Simader, C., & Schmidt-Erfurth, U. M. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.05.032 · Cited by 84
Anti-VEGF for the Management of Diabetic Macular Edema
Stefanini, F. R., Badaró, E., Falabella, P., Koss, M., Farah, M. E., & Maia, M. (2014) · Journal of Immunology Research · doi:10.1155/2014/632307 · Cited by 81
ENDOPHTHALMITIS ASSOCIATED WITH INTRAVITREAL INJECTIONS
Tabandeh, H., Boscia, F., Sborgia, A., Ciracì, L., Dayani, P. N., Mariotti, C., Furino, C., & Flynn, H. W. (2013) · Retina · doi:10.1097/iae.0000000000000008 · Cited by 83
Wang, F., Yu, S., Liu, K., Chen, F.-E., Song, Z., Zhang, X., Xu, X., & Sun, X. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.07.083 · Cited by 80
Grewal, D. S., Gill, M. K., Sarezky, D., Lyon, A. T., & Mirza, R. G. (2014) · Eye · doi:10.1038/eye.2014.101 · Cited by 80
Gianniou, C., Dirani, A., Jang, L., & Mantel, I. (2015) · Retina · doi:10.1097/iae.0000000000000465 · Cited by 81
Using Genome Sequence to Enable the Design of Medicines and Chemical Probes
Angelbello, A. J., Chen, J. L., Childs‐Disney, J. L., Zhang, P., Wang, Z.-F., & Disney, M. D. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00504 · Cited by 81
Marina, M. E., Roman, I. I., Constantin, A.-M., Mihu, C. M., & Tataru, A. D. (2015) · Medicine and Pharmacy Reports · doi:10.15386/cjmed-494 · Cited by 81
Stereotactic Radiotherapy for Neovascular Age-related Macular Degeneration
Jackson, T. L., Chakravarthy, U., Kaiser, P. K., Slakter, J. S., Jan, E., Bandello, F. M., O’Shaughnessy, D., Gertner, M. E., Danielson, L., & Moshfeghi, D. M. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.02.016 · Cited by 80
Klettner, A., Kauppinen, A., Błasiak, J., Roider, J., Salminen, A., & Kaarniranta, K. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.04.013 · Cited by 83
What's fueling the biotech engine—2010 to 2011
Aggarwal, S. (2011) · Nature Biotechnology · doi:10.1038/nbt.2060 · Cited by 79
Jaffe, G. J., Kaiser, P. K., Thompson, D. E., Gibson, A., Saroj, N., Vitti, R., Berliner, A. J., & Heier, J. S. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.05.016 · Cited by 79
DeCroos, F. C., Reed, D. C., Adam, M. K., Salz, D. A., Gupta, O. P., Ho, A. C., & Regillo, C. D. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.06.002 · Cited by 81
Schauwvlieghe, A.-S. M. E., Dijkman, G., Hooymans, J. M. M., Verbraak, F. D., Hoyng, C. B., Dijkgraaf, M. G. W., Pető, T., Vingerling, J. R., & Schlingemann, R. O. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153052 · Cited by 87
Shienbaum, G., Gupta, O. P., Fecarotta, C., Patel, A. H., Kaiser, R. S., & Regillo, C. D. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.08.011 · Cited by 77
Traine, P. G., Pfister, I. B., Zandi, S., Spindler, J., & Garweg, J. G. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.01.018 · Cited by 78
Maloney, M. H., Payne, S. R., Herrin, J. S., Sangaralingham, L. R., Shah, N. D., & Barkmeier, A. J. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.07.062 · Cited by 78
Antiangiogenic Therapy for Ischemic RetinopathiesPreprint
Al-Latayfeh, M., Silva, P. S., Sun, J. K., & Aiello, L. P. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006411 · Cited by 77
Fernandes, A. R., Zielińska, A., Sánchez‐López, E., dos Santos, T., García, M. L., Silva, A. M., Karczewski, J., & Souto, E. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052592 · Cited by 82
Nakata, I., Yamashiro, K., Nakanishi, H., Akagi-Kurashige, Y., Miyake, M., Tsujikawa, A., Matsuda, F., & Yoshimura, N. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.06.007 · Cited by 75
INTRAVITREAL RANIBIZUMAB VERSUS BEVACIZUMAB FOR TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION
Iacono, P., Parodi, M. B., Papayannis, A., Kontadakis, S., Sheth, S., Cascavilla, M. L., & Bandello, F. M. (2012) · Retina · doi:10.1097/iae.0b013e31826956b7 · Cited by 75
Epimacular Brachytherapy for Neovascular Age-related Macular Degeneration
Dugel, P. U., Bebchuk, J. D., Nau, J. A., Reichel, E., Singer, M. A., Barak, A., Binder, S., & Jackson, T. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.07.068 · Cited by 76
Bailey, S. T., Thaware, O. C., Wang, J., Hagag, A. M., Zhang, X., Flaxel, C. J., Lauer, A. K., Hwang, T. S., Lin, P., Huang, D., et al. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.03.008 · Cited by 81
Daïen, V., Finger, R. P., Talks, J. S., Mitchell, P., Wong, T. Y., Sakamoto, T., Eldem, B., & Korobelnik, J. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-317434 · Cited by 76
Khanani, A. M., Callanan, D., Dreyer, R. F., Chen, S., Howard, J. G., Hopkins, J. J., Lin, C.-Y., Lorenz-Candlin, M., Makadia, S., Patel, S., et al. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.11.004 · Cited by 77
Csaky, K. G., Dugel, P. U., Pierce, A. J., Fries, M. A., Kelly, D. S., Danis, R. P., Wurzelmann, J. I., Xu, C., Hossain, M. S., & Trivedi, T. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.09.036 · Cited by 75
Mokwa, N., Ristau, T., Keane, P. A., Kirchhof, B., Sadda, S. R., & Liakopoulos, S. (2013) · Journal of Ophthalmology · doi:10.1155/2013/385915 · Cited by 77
Mantel, I., Niderprim, S.-A., Gianniou, C., Deli, A., & Ambresin, A. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-304556 · Cited by 75
Bevacizumab versus Ranibizumab for AMD
Rosenfeld, P. J. (2011) · New England Journal of Medicine · doi:10.1056/nejme1103334 · Cited by 78
Sustained delivery of a HIF-1 antagonist for ocular neovascularization
Iwase, T., Fu, J., Yoshida, T., Muramatsu, D., Miki, A., Hashida, N., Lu, L., Oveson, B. C., Silva, R. L. E., Seidel, C. P., et al. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.10.008 · Cited by 75
Martín, D. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.12.019 · Cited by 76
Neovascular Age-Related Macular Degeneration
Shao, J., Choudhary, M. M., & SCHACHAT, A. P. (2015) · Developments in ophthalmology · doi:10.1159/000438969 · Cited by 78
Muether, P. S., Hermann, M. M., Viebahn, U., Kirchhof, B., & Fauser, S. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.07.041 · Cited by 74
Fernández‐Robredo, P., Sancho, A., Johnen, S., Recalde, S., Gama, N., Thumann, G., Gröll, J., & García‐Layana, A. (2014) · Journal of Ophthalmology · doi:10.1155/2014/510285 · Cited by 77
Cost-Effectiveness of Treatment of Diabetic Macular Edema
Pershing, S., Enns, E. A., Matesic, B., Owens, D. K., & Goldhaber‐Fiebert, J. D. (2014) · Annals of Internal Medicine · doi:10.7326/m13-0768 · Cited by 73
Bo, Q., Yan, Q., Shen, M., Song, M., Sun, M., Yu, Y., Rosenfeld, P. J., Wang, F., & Sun, X. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.0449 · Cited by 75
Singh, R. P., Srivastava, S. K., Ehlers, J. P., Bedi, R., SCHACHAT, A. P., & Kaiser, P. K. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-304798 · Cited by 75
Kaiser, P. K., Wykoff, C. C., Singh, R. P., Khanani, A. M., Diana, V., Patel, H., & Patel, N. (2021) · Retina · doi:10.1097/iae.0000000000003194 · Cited by 73
Anti-VEGF Treatment of Corneal Neovascularization
Keating, A. M., & Jacobs, D. S. (2011) · The Ocular Surface · doi:10.1016/s1542-0124(11)70035-0 · Cited by 74
Brown, D. M., Tuomi, L., & Shapiro, H. (2012) · Retina · doi:10.1097/iae.0b013e318263cedf · Cited by 74
Abedi, F., Wickremasinghe, S., Richardson, A. J., Islam, A. F. M., Guymer, R. H., & Baird, P. N. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.01.014 · Cited by 74
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Moja, L., Lucenteforte, E., Kwag, K. H., Bertelè, V., Campomori, A., Chakravarthy, U., D’Amico, R., Dickersin, K., Kodjikian, L., Lindsley, K. B., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011230 · Cited by 75
Aflibercept-Related Sterile Inflammation
Hahn, P., Kim, J. E., Stinnett, S., Chung, M. M., Dugel, P. U., Flynn, H. W., Huang, S. S., Sadda, S. R., & Mahmoud, T. H. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.018 · Cited by 74
Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections
Sharma, S., Johnson, D. E., Abouammoh, M. A., Hollands, S., & Brissette, A. R. (2012) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2012.03.026 · Cited by 74
Regillo, C. D., BUSBEE, B. G., Ho, A. C., Ding, B., & Hašková, Z. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.07.034 · Cited by 75
Current advances in the treatment of neovascular age-related macular degeneration
Villegas, V. M., Aranguren, L. A., Kovach, J. L., Schwartz, S. G., & Flynn, H. W. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1213240 · Cited by 75
Abdelfattah, N. S., Al‐Sheikh, M., Pitetta, S., Mousa, A., Sadda, S. R., Wykoff, C. C., Wykoff, C. C., Croft, D. E., Brown, D. M., Wang, R. C., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.10.002 · Cited by 73
Moorthy, R. S., London, N. J. S., Garg, S. J., & Cunningham, E. T. (2013) · Current Opinion in Ophthalmology · doi:10.1097/01.icu.0000434534.32063.5c · Cited by 74
The value of intraoperative optical coherence tomography imaging in vitreoretinal surgery
Ehlers, J. P., Tao, Y. K. K., & Srivastava, S. K. (2014) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000044 · Cited by 73
Ng, D. S., Yip, Y. W. Y., Bakthavatsalam, M., Chen, L. J., Ng, T. K., Lai, T. Y. Y., Pang, C. P., & Brelen, M. E. (2017) · Scientific Reports · doi:10.1038/srep45081 · Cited by 74
Clinical Characteristics and Current Treatment of Age-Related Macular DegenerationPreprint
Yonekawa, Y., & Kim, I. K. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017178 · Cited by 75
Storey, P. P., Pancholy, M. S., Wibbelsman, T. D., Obeid, A., Su, D., Borkar, D. S., Garg, S. J., & Gupta, O. P. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.037 · Cited by 74
Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders
Hang, A., Feldman, S., Amin, A., Ochoa, J. R., & Park, S. S. (2023) · Pharmaceuticals · doi:10.3390/ph16081140 · Cited by 77
Differential DNA methylation identified in the blood and retina of AMD patients
Oliver, V. F., Jaffe, A. E., Song, J., Wang, G., Zhang, P., Branham, K. E. H., Swaroop, A., Eberhart, C. G., Zack, D. J., Qian, J. X., et al. (2015) · Epigenetics · doi:10.1080/15592294.2015.1060388 · Cited by 72
Abraham, I. L., Rakic, LEYS, A. M., Brie, Denhaerynck, Pacheco, Vancayzeele, Hermans, & MacDonald, K. (2013) · Clinical ophthalmology · doi:10.2147/opth.s49385 · Cited by 73
Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994–2007
Day, S., Acquah, J., Lee, P. P., Mruthyunjaya, P., & Sloan, F. A. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.05.008 · Cited by 72
Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review.
Waugh, N., Loveman, E., Colquitt, J., Royle, P., Yeong, J., Hoad, G. V., & Lois, N. (2018) · Health Technology Assessment · doi:10.3310/hta22270 · Cited by 61
Scott, A. W., & Bressler, S. B. (2013) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32835fefee · Cited by 71
Regulation of signaling events involved in the pathophysiology of neovascular AMD.
Wang, H., & Hartnett, M. E. (2016) · Europe PMC (PubMed Central) · Cited by 72
Therapies for Macular Edema Associated with Branch Retinal Vein Occlusion
Ehlers, J. P., Kim, S. J., Yeh, S., Thorne, J. E., Mruthyunjaya, P., Schoenberger, S. D., & Bakri, S. J. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.03.060 · Cited by 71
Stewart, M. W. (2012) · Clinical ophthalmology · doi:10.2147/opth.s33372 · Cited by 71
Cho, H. J., Kim, H. S., Jang, Y. S., Han, J. I., Lew, Y. J., Lee, T. G., Kim, C. G., & Kim, J. W. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.07.001 · Cited by 71
Lee, J. Y., Folgar, F. A., Maguire, M. G., Ying, G., Toth, C. A., Martin, D. F., & Jaffe, G. J. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.06.013 · Cited by 71
Alves, C. H., Fernandes, R., Santiago, A. R., & Ambrósio, A. F. (2020) · Cells · doi:10.3390/cells9051217 · Cited by 73
Goldberg, R. A., Flynn, H. W., Miller, D., Gonzalez, S., & Isom, R. F. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.12.009 · Cited by 70
Yang, S., Li, T., Jia, H., Gao, M., Li, Y., Wan, X., Huang, Z., Li, M., Zhai, Y., Li, X., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj2177 · Cited by 71
Implantable MicroPump for Drug Delivery in Patients with Diabetic Macular Edema
Humayun, M. S., Santos, A., Altamirano, J. C., Ribeiro, R., González, R., de la Rosa, A., Shih, J., Pang, C., Jiang, F., Calvillo, P., et al. (2014) · Translational Vision Science & Technology · doi:10.1167/tvst.3.6.5 · Cited by 72
for the PF-04523655 Study Group, Nguyen, Q. D., Schachar, R. A., Nduaka, C. I., Sperling, M., Basile, A. S., Klamerus, K. J., Chi-Burris, K., Yan, E., Paggiarino, D. A., et al. (2012) · Eye · doi:10.1038/eye.2012.106 · Cited by 70
Chew, E. Y., Clemons, T. E., Bressler, S. B., Elman, M. J., Danis, R. P., Domalpally, A., Heier, J. S., Kim, J. E., & Garfinkel, R. A. (2014) · Contemporary Clinical Trials · doi:10.1016/j.cct.2014.02.003 · Cited by 67
Zhao, M., Mantel, I., Gélizé, E., Li, X., Xie, X., Arboleda, A., Séminel, M., Levy, R., Dernigoghossian, M., Prunotto, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08125-6 · Cited by 72
Senabouth, A., Daniszewski, M., Lidgerwood, G. E., Liang, H. H., Hernández, D., Mirzaei, M., Keenan, S. N., Zhang, R., Han, X., Neavin, D. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31707-4 · Cited by 75
Solomon, S. D., Lindsley, K. B., Krzystolik, M. G., Vedula, S. S., & Hawkins, B. S. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.09.002 · Cited by 68
DeCroos, F. C., Toth, C. A., Stinnett, S. S., Heydary, C. S., Burns, R., & Jaffe, G. J. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.06.040 · Cited by 67
Sukgen, E. A., & Koçluk, Y. (2018) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-018-4168-5 · Cited by 68
Zheng, Y., Sahni, J., Campa, C., Stangos, A. N., Raj, A., & Harding, S. P. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.07.030 · Cited by 68
Dong, A., Seidel, C. P., Snell, D. C., Ekawardhani, S., Ahlskog, J., Baumann, M. J., Shen, J., Iwase, T., Tian, J., Stevens, R., et al. (2013) · Angiogenesis · doi:10.1007/s10456-013-9402-5 · Cited by 68
Fauser, S., & Muether, P. S. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-308264 · Cited by 68
Gale, R. P., Mahmood, S., Devonport, H., Patel, P. J., Ross, A. H., Walters, G., Downey, L., Elsherbiny, S., Freeman, M., Berry, S., et al. (2019) · Eye · doi:10.1038/s41433-018-0300-3 · Cited by 69
Kusuhara, S., Fukushima, Y., Fukuhara, S., Jakt, L. M., Okada, M., Shimizu, Y., Hata, M., Nishida, K., Negi, A., Hirashima, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045858 · Cited by 66
Antiangiogenesis therapy: an update after the first decade
Falco, S. D. (2014) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2014.29.1.1 · Cited by 72
Taylor, S. C., Huecker, J. B., Gordon, M. O., Vollman, D. E., & Apte, R. S. (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.1678 · Cited by 66
Mukwaya, A., Jensen, L. D., & Lagali, N. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00566-2 · Cited by 65
Schaal, S., Sigford, D. K., Reddy, S., & Mollineaux, C. (2015) · Clinical ophthalmology · doi:10.2147/opth.s77067 · Cited by 67
Neovascular Age-Related Macular Degeneration
Veritti, D., Sarao, V., & Lanzetta, P. (2012) · Ophthalmologica · doi:10.1159/000337154 · Cited by 66
Toalster, N., Russell, M. W., & Ng, P. (2013) · Retina · doi:10.1097/iae.0b013e3182831265 · Cited by 66
Preferred therapies for neovascular age-related macular degeneration
Chiang, A., & Regillo, C. D. (2011) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32834597d9 · Cited by 66
Lad, E. M., Hammill, B. G., Qualls, L. G., Wang, F., Cousins, S. W., & Curtis, L. H. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.05.014 · Cited by 66
Metadata
- Authors
- The CATT Research Group
- Corresponding author
- The CATT Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-19
- Volume
- 364
- Issue
- 20
- Pages
- 1897-1908
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3157322
- OpenAlex
- W1481978003
- Cited by
- 2,669
- References
- 21
- Citations by year
- 2026: 78 · 2025: 91 · 2024: 116 · 2023: 111 · 2022: 127 · 2021: 164 · 2020: 195 · 2019: 151 · 2018: 168 · 2017: 177 · 2016: 199 · 2015: 238 · 2014: 264 · 2013: 248 · 2012: 265
- FWCI
- 254.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Eye Institute (U10EY017825, U10EY017826, U10EY017823, U10EY017828)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neovascular age-related macular degeneration, ranibizumab, bevacizumab, intravitreal injection, anti-VEGF therapy, visual acuity, central retinal thickness, treatment schedule, non-inferiority, serious adverse events, off-label drug use, anti-angiogenic therapy, comparative efficacy and safety, hospitalization
- MeSH terms
- Bevacizumab, Ranibizumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Cardiovascular Diseases, Drug Administration Schedule, Female, Humans, Macular Degeneration, Male, Middle Aged, Retina, Therapeutic Equivalency, Visual Acuity, Proportional Hazards Models, Single-Blind Method, Off-Label Use, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
